Purpose of Review <p>This review examines the pathopythiology, diagnostic features, and management of gastric antral vascular ectasia (GAVE) and portal hypertensive gastropathy (PHG).</p> Recent Findings <p>GAVE and PHG are distinct lesions that often present with evidence of chronic occult bleeding, often manifesting as IDA. GAVE is typically idiopathic, with a distinctive “watermelon stomach” appearance, although alternative morphologies exist. PHG is closely linked to portal hypertension, and features a mosaic/ snakeskin-like mucosal pattern. Histological assessment helps differentiate GAVE and PHG when endoscopic features overlap, especially in cirrhosis. Management differs significantly; PHG treatment focuses on reducing portal pressure (beta-blockade, TIPS or occasionally liver transplantation). Endoscopic management of PHG remain limited due to the diffuse nature of bleeding (e.g. argon plasma coagulation (APC) and hemospray). For GAVE, endoscopic ablative therapies including APC or banding are typically effective, and radiofrequency ablation (RFA) appears to be effective for refractory GAVE.</p> Summary <p>Differentiating GAVE and PHG is crucial due to their distinct management approaches.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Endoscopic Treatments for Portal Hypertensive Gastropathy (PHG) and Gastric Antral Vascular Ectasia (GAVE)

  • Ali Khalifa,
  • Don C. Rockey

摘要

Purpose of Review

This review examines the pathopythiology, diagnostic features, and management of gastric antral vascular ectasia (GAVE) and portal hypertensive gastropathy (PHG).

Recent Findings

GAVE and PHG are distinct lesions that often present with evidence of chronic occult bleeding, often manifesting as IDA. GAVE is typically idiopathic, with a distinctive “watermelon stomach” appearance, although alternative morphologies exist. PHG is closely linked to portal hypertension, and features a mosaic/ snakeskin-like mucosal pattern. Histological assessment helps differentiate GAVE and PHG when endoscopic features overlap, especially in cirrhosis. Management differs significantly; PHG treatment focuses on reducing portal pressure (beta-blockade, TIPS or occasionally liver transplantation). Endoscopic management of PHG remain limited due to the diffuse nature of bleeding (e.g. argon plasma coagulation (APC) and hemospray). For GAVE, endoscopic ablative therapies including APC or banding are typically effective, and radiofrequency ablation (RFA) appears to be effective for refractory GAVE.

Summary

Differentiating GAVE and PHG is crucial due to their distinct management approaches.